Article
Author(s):
Updated information includes drug-drug interaction.
Updated information includes drug-drug interaction.
The FDA announced Wednesday it was updating the labels for a pair of drugs that treat HIV with new information.
The labels for dolutegravir (Tivicay) and abacavir/dolutegravir/lamivudine (Triumeq) will now include updated information on drug-drug interaction, such as:
The FDA also updated Section 7 Drug Interactions that state in vitro, dolutegravir is not a substrate of OATP1B1 or OATP1B3.
“Additonally, the TRIUMEQ label, section 6.1 Less Common Adverse Reactions Observed in Clinical Trials section was updated to be consistent with the TIVICAY label as follows: Psychiatric: Suicidal ideation, attempt, behavior, or completion,” the FDA said in a statement. “These events were observed primarily in subjects with a pre-existing history of depression or other psychiatric illness.”
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.